Saltar al contenido
Merck

Defining immunological impact and therapeutic benefit of mild heating in a murine model of arthritis.

PloS one (2015-03-21)
Chen-Ting Lee, Kathleen M Kokolus, Nicholas D Leigh, Maegan Capitano, Bonnie L Hylander, Elizabeth A Repasky
RESUMEN

Traditional treatments, including a variety of thermal therapies have been known since ancient times to provide relief from rheumatoid arthritis (RA) symptoms. However, a general absence of information on how heating affects molecular or immunological targets relevant to RA has limited heat treatment (HT) to the category of treatments known as "alternative therapies". In this study, we evaluated the effectiveness of mild HT in a collagen-induced arthritis (CIA) model which has been used in many previous studies to evaluate newer pharmacological approaches for the treatment of RA, and tested whether inflammatory immune activity was altered. We also compared the effect of HT to methotrexate, a well characterized pharmacological treatment for RA. CIA mice were treated with either a single HT for several hours or daily 30 minute HT. Disease progression and macrophage infiltration were evaluated. We found that both HT regimens significantly reduced arthritis disease severity and macrophage infiltration into inflamed joints. Surprisingly, HT was as efficient as methotrexate in controlling disease progression. At the molecular level, HT suppressed TNF-α while increasing production of IL-10. We also observed an induction of HSP70 and a reduction in both NF-κB and HIF-1α in inflamed tissues. Additionally, using activated macrophages in vitro, we found that HT reduced production of pro-inflammatory cytokines, an effect which is correlated to induction of HSF-1 and HSP70 and inhibition of NF-κB and STAT activation. Our findings demonstrate a significant therapeutic benefit of HT in controlling arthritis progression in a clinically relevant mouse model, with an efficacy similar to methotrexate. Mechanistically, HT targets highly relevant anti-inflammatory pathways which strongly support its increased study for use in clinical trials for RA.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Hidróxido de potasio, ACS reagent, ≥85%, pellets
Sigma-Aldrich
Dodecilsulfatosódico, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Hidróxido de potasio, reagent grade, 90%, flakes
Sigma-Aldrich
Dodecilsulfatosódico, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Formaldehído solution, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
Potassium hydroxide solution, 45 wt. % in H2O
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Hidróxido de potasio, semiconductor grade, pellets, 99.99% trace metals basis (Purity excludes sodium content.)
SAFC
Formaldehído solution, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Dodecilsulfatosódico, ACS reagent, ≥99.0%
Sigma-Aldrich
Dodecilsulfatosódico, ReagentPlus®, ≥98.5% (GC)
Supelco
Potassium hydroxide solution, volumetric, 8.0 M KOH (8.0N)
Sigma-Aldrich
Hidróxido de potasio, ≥85% KOH basis, pellets, white
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 20% in H2O
SAFC
Methotrexate
Sigma-Aldrich
Formaldehído solution, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
3,3′,5,5′-Tetrametilbencidina, ≥99%
Sigma-Aldrich
Dodecilsulfatosódico, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Formaldehído solution, for molecular biology, BioReagent, ≥36.0% in H2O (T)